Laboratory for Molecular Diagnostics
Center for Nephrology and Metabolic Disorders
Moldiag Diseases Genes Support Contact

Angiopoietin-like protein 8

The ANGPTL8 gene encodes an inhibitor of lipolysis. Therefore it is a probably candidate for mutation in hypertriglyceridemia.

Genetests:

Clinic Method Carrier testing
Turnaround 5 days
Specimen type genomic DNA
Research Method Genomic sequencing of the entire coding region
Turnaround 25 days
Specimen type genomic DNA

Related Diseases:

Combined familial hyperlipidemia with dysfunctional VLDL metabolism
ANGPTL8
APOA1
APOA4
APOA5
APOC3
CETP
GALNT2
LCAT
LIPC
LIPG
LPL
RXRG
USF1

References:

1.

Cefalù AB et al. () Identification of a novel LMF1 nonsense mutation responsible for severe hypertriglyceridemia by targeted next-generation sequencing.

external link
2.

None (2012) Lipasin, a novel nutritionally-regulated liver-enriched factor that regulates serum triglyceride levels.

external link
3.

Quagliarini F et al. (2012) Atypical angiopoietin-like protein that regulates ANGPTL3.

external link
4.

Tseng YH et al. (2014) Chromosome 19 open reading frame 80 is upregulated by thyroid hormone and modulates autophagy and lipid metabolism.

external link
5.

Gusarova V et al. (2014) ANGPTL8/betatrophin does not control pancreatic beta cell expansion.

external link
6.

NCBI article

NCBI 55908 external link
7.

OMIM.ORG article

Omim 616223 external link
8.

Wikipedia article

Wikipedia EN (ANGPTL8) external link
Update: Aug. 14, 2020
Copyright © 2005-2020 by Center for Nephrology and Metabolic Disorders, Dr. Mato Nagel, MD
Albert-Schweitzer-Ring 32, D-02943 Weißwasser, Germany, Tel.: +49-3576-287922, Fax: +49-3576-287944
Sitemap | Webmail | Disclaimer | Privacy Issues